Ilenia Calcaterra: Beyond Bleeding Control Emicizumab and the Evolution of Joint Health in Hemophilia A
Ilenia Calcaterra, Consultant Physician in Internal Medicine and Assistant Professor at the University of Naples Federico II, shared a post on LinkedIn about a recent article she and her colleagues co-authored, published in Haemophilia, adding:
“Beyond bleeding control: what happens to joint health during emicizumab prophylaxis?
Pleased to share the results of the RESOLVE Study, now published in Haemophilia.
In this multicentre real-world study, we evaluated the longitudinal evolution of joint health in adults with severe haemophilia A after switching to emicizumab, combining clinical assessment with point-of-care ultrasound and HEAD-US.
After at least 2 years of prophylaxis, emicizumab was associated with a marked reduction in bleeding, with 76.9 percent of patients reporting zero joint bleeds.
But the most interesting finding came from the ultrasound assessment: among joints with hypertrophic synovium at baseline, 53.7 percent showed improvement or complete resolution.
At the same time, persistent synovial hypertrophy remained detectable in a relevant proportion of joints, particularly in the presence of pre-existing osteochondral damage.
As treatment efficacy continues to improve, our focus should increasingly move beyond ABR, integrating imaging-based surveillance, musculoskeletal assessment and individualized strategies aimed not only at preventing bleeding, but at preserving and whenever possible restoring joint health.
A great collaborative effort involving the haemophilia centres of Naples, Rome and Catanzaro”
Title: Changes in Hypertrophic Synovium Status in Adult Patients With Severe Hemophilia A Receiving Emicizumab Prophylaxis: The RESOLVE Study
Authors: Matteo Nicola Dario Di Minno, Erminia Baldacci, Ilenia Lorenza Calcaterra, Guido D’Errico, Cristina Santoro, Alessandra Strangio, Silvia Sorella, Marzia Leotta, Rita Carlotta Santoro
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 16, 2026, 13:10Emanuel Sueldo: CAHT 2026 Celebrates Scientific Progress and Team Achievements
-
Oct 16, 2026, 13:05Maha Othman: Queen’s Health Sciences Advances CAT Risk Models and Pediatric ISTH-BAT Cut-Offs
-
Oct 16, 2026, 13:03Thrombosis Awareness Must Lead to Timely Action – Roche
-
Oct 16, 2026, 12:49Wolfgang Miesbach: 5-Year CBDR Data Confirms Emicizumab Safety and Efficacy in Hemophilia A
-
Oct 16, 2026, 12:40Edward Lee Carter: How Factor XI Inhibition Could Transform Anticoagulation Therapy
-
Oct 16, 2026, 12:40Marc Carrier: Looking Ahead to ISTH 2027 in Vancouver
-
Oct 16, 2026, 12:30Bob Lempke: How One Blood Donation Can Save Up to Three Lives
-
Oct 16, 2026, 12:30Why VWF Therapies Belong on the EU Critical Medicines List – EHC
-
Oct 16, 2026, 12:17Exploring Endothelial Cells, Genetic Fate Mapping, and Revascularization – ISTH